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1684-1182/Copyright ª 2015, TaiwanAbstract Background: We aimed to report the implementation of an antimicrobial steward-
ship program (ASP) guided by clinically significant cultures in a hospital to assess its pharma-
ceutical, microbiological, financial, and outcome effects.
Methods: A 3-year cohort study of an antimicrobial restriction policy implementation was per-
formed. The ASP with culture-guided de-escalation of antibiotics was instituted in a local hos-
pital since January 1, 2012. The cost of antimicrobials, defined daily dose (DDD), susceptibility
to antimicrobials, and outcome of all admitted patients were calculated and evaluated before
and after the ASP implementation.
Results: Average monthly length of stay of admitted patients decreased from 7.8  0.5 days in
2011 to 6.9  0.3 days in 2013 (p < 0.001). The average monthly cost of antimicrobials
decreased 46.9% from US$30,146.8 in 2011 to US$16,021.3 in 2013 (p < 0.001). Totalof Nursing, Jen-Teh Junior College of Medicine, Nursing and Management, No. 79-9, Sha-Luen-Hu,
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http://dx.doi.org/10.1016/j.jmii.201intravenous antimicrobial DDDs per 100 bed-days of the inpatients were 66.9, 54.1 and 48.4 in
2011, 2012 and 2013, respectively. A total of 18.6 DDDs per 100 bed-days of inpatients (27.7%)
decreased from 2011 to 2013. By comparing data in 2013 to those in 2011, the ASP reduced
antimicrobial resistance of Gram-positive bacteria (p Z 0.013), Gram-negative bacteria
(p < 0.001), and predominant species (all p < 0.05). The yearly mortality also decreased from
1.3% in 2011 to 1.1% in 2012 and 1.0% in 2013.
Conclusions: The ASP with a culture-guided de-escalation of antibiotics successfully reduced
length of stay, mortality, the cost of antimicrobials, DDDs, and antimicrobial resistance rate,
and that is highly recommended for local hospitals.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Antibiotic overuse and resistance problems have become a
major public health issue worldwide.1e8 In addition to
increased treatment expenditures, inappropriate or
excessive antibiotic usage results in the emergence and
spread of antibiotic-resistant bacteria, which lead to
increased morbidity, inpatient stays, and higher mortal-
ity.9e18 The use of antimicrobials against bacterial in-
fections is pivotal in the emergence of antimicrobial
resistance of bacteria due to antibiotic selective pres-
sure.4e6 In order to improve patient outcomes by reducing
the unintended consequences of antibiotic use, the Infec-
tious Disease Society of America, the Society for Healthcare
Epidemiology of America and the Centers for Disease Con-
trol, Taiwan have published guidelines for developing
antimicrobial stewardship programs (ASPs).1e3
Procalcitonin-guided or blood-culture-guided de-escala-
tion strategies have been shown to reduce antimicrobial
exposure without any impact on the mortality rate and
treatment failure in critically ill patients.19e21 However,
procalcitonin and blood culture are seldom available in
noncritical patients. For noncritical patients, it is more
feasible to guide usage of antibiotics by clinically significant
cultures from urine, pus, sputum, blood, and stools.
It is difficult to implement an ASP in a local, small hospital
without adequate resources.8 The Anatomical Therapeutic
Chemical Classification/Defined Daily Dose (ATC/DDD)
classification from the World Health Organization in 2013,
widely used as a standard to measure drug use in hospitals
and community settings, was used to calculate antibiotic
usage, which was presented as the numbers of DDDs and
DDDs/100 bed-days.22e26 In this study, we monitored the
efficacy of the ASP on DDD, antimicrobial cost, and bacterial
susceptibility before and after ASP implementation.Methods
Study designs
All patients admitted to Nan Men General Hospital (NMGH),
a 141-bed local hospital in Northern Taiwan, including 116
acute illness beds, 15 hemodialysis beds, and 10 intensive
care center beds, from 2011 to 2013 were enrolled in thisu C-T, et al., Decreased antimicro
stewardship program in a local ho
5.10.006study. Prior to January 2012, traditional antimicrobial re-
striction policy other than the culture-based regimen was
performed in this hospital. The Antibiotic Restriction
Committee (ARC) monitored and controlled the consump-
tion of all antimicrobials. All ARC doctors were senior
physicians and well trained in antibiotic control. Comput-
erized Physician Order Entry (CPOE) and Computerized
Antimicrobial Approval System (CAAS) were also imple-
mented. The antibiotic prescriptions that failed to pass the
above audit were discontinued within 48 hours. Pre-
scriptions of restricted and unrestricted antimicrobials,
antibiotic prescriptions in the outpatient department, and
prophylactic antimicrobials for surgery were post-
prescriptively audited under the control of infectious dis-
ease specialists. Pediatric patients were the most
frequently admitted patients, contributing to more than
half of the total admitted to this hospital (Table 1). A new
antimicrobial restriction policy with a culture-guided ASP
was implemented in this hospital and supported by a
medical center from January 1, 2012. Routine monitoring of
antibiotic use based on infected culture by the web-based
justification was initiated on January 1, 2012 to decrease
antimicrobial resistance and expenditure. The new re-
striction policy was initially implemented on January 1,
2012. Before the ASP, the specialists, administration and
technologists of NMGH were well trained by Chang Gung
Memorial Hospital (CGMH), a 3700-bed teaching medical
center. However, NMGH is not part of a larger CGMH system
that shares/pools resources before ASP implementation.
This study was designed as a cohort “before and after”
study to compare pharmaceutical, microbiological and
financial changes before and after implementation of the
policy over a 3-year period from 2011 to 2013, and data in
2011 (before the culture-guided ASP) were used as controls.
All 27 physicians remained the same during this study
period. This study was approved by the Institutional Review
Board of NMGH.
New antimicrobial restriction policy
The new antimicrobial restriction policy of the culture-
guided ASP was created by the ARC, including infectious
disease physicians, clinical pharmacists, microbiologists,
and administrators of NMGH and CGMH, and it was imple-
mented on January 1, 2012. All prescriptions of restrictedbial resistance and defined daily doses after implementation of a
spital, Journal of Microbiology, Immunology and Infection (2015),
Table 1 Patient characteristics during baseline (2011) and intervention periods (2012e2013).
Patient characteristics n (%), 2011
(n Z 4181)
n (%), 2012
(n Z 4230)
n (%), 2013
(n Z 4435)
p
(Data2012 vs. Data2011)
p
(Data2013 vs. Data2011)
Age distribution
 10 y 1653 (39.5) 1674 (39.6) 1729 (39.0) 0.971 0.601
11e20 y 1253 (30.0) 1298 (30.7) 1296 (29.2) 0.475 0.448
21e60 y 367 (8.8) 375 (8.9) 387 (8.7) 0.888 0.932
61e80 y 558 (13.3) 557 (13.2) 584 (13.8) 0.810 0.500
> 80 y 350 (8.4) 326 (7.7) 439 (9.2) 0.229 0.164
Male sex 2035 (48.7) 2075 (49.1) 2196 (49.5) 0.726 0.434
Primary ICD-9 diagnosis codes
Pulmonary disease 1367 (32.7) 1375 (32.9) 1397 (31.5) 0.788 0.464
Gastrointestinal disease 1045 (25.0) 1054 (24.9) 1157 (26.1) 0.071 0.550
Urinary tract disease 427 (10.2) 437 (10.3) 442 (10.0) 0.858 0.704
Neoplastic disease 346 (8.3) 356 (8.4) 362 (8.2) 0.816 0.848
Cardiac disease 254 (6.1) 263 (6.2) 275 (6.2) 0.786 0.808
Soft tissue disease 287 (6.9) 295 (7.0) 306 (6.9) 0.843 0.948
Neurological disease 287 (6.9) 294 (7.0) 316 (7.1) 0.939 0.636
Endocrinal disease 168 (4.0) 156 (3.7) 180 (4.1) 0.431 0.873
Pitt bacteremia score
 4 points 416 (9.9) 430 (10.2) 433 (9.8) 0.742 0.772
3 points 632 (15.1) 627 (14.8) 673 (15.2) 0.706 0.939
2 points 937 (22.4) 966 (22.8) 1031 (23.2) 0.641 0.356
 1 point 2196 (52.5) 2207 (52.2) 2298 (51.8) 0.749 0.511
Charlson score
 4 points 209 (5.0) 219 (5.2) 227 (5.1) 0.710 0.800
3 points 266 (6.4) 276 (6.5) 271 (6.1) 0.761 0.629
2 points 370 (8.8) 376 (8.9) 385 (8.7) 0.949 0.782
1 point 424 (10.1) 432 (10.2) 453 (10.2) 0.913 0.911
0 points 2912 (69.6) 2927 (69.2) 3099 (69.9) 0.653 0.818
ICD-9 Z International Classification of Diseases, 9th Revision.
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+ MODELantimicrobials for admitted patients required approval
from ARC physicians by CAAS to prevent suboptimal regi-
mens. For the second review, the microbiological labora-
tory sent an alarm message for results of positive cultures,
including urine, pus, sputum, blood, and stools, to the
prescribed attending doctor and preassigned ARC physician
by mobile phone. Both the prescribed attending doctor and
preassigned ARC physician evaluated the clinical signifi-
cance of the microbial cultures, and re-evaluated all anti-
microbial agents, relevant medical information, updated
culture results, and antimicrobial susceptibilities within a
48-hour buffer period through the bidirectional communi-
cation platform. Assessment of the clinical significance
(colonization or infection) of each bacterium and the type
of infection was performed by infectious diseases special-
ists and followed the US Centers for Disease Control and
Prevention criteria, which was defined in the presence of
not only bacteria from clinical specimens, but also clinical
symptoms or signs of infection.27 After each new clinically
significant culture was reported, the attending doctor
adjusted the antimicrobials by CPOE according to the cul-
ture result, and ARC physician audited the new prescription
by CAAS.
This policy was based on five components in detail: (1)
adjust antimicrobials according to the results of clinically
significant cultures; (2) for prospective audit, establishing
an antibiotic audit via a web-based CAAS verified by thePlease cite this article in press as: Wu C-T, et al., Decreased antimicro
clinical culture-guided antimicrobial stewardship program in a local ho
http://dx.doi.org/10.1016/j.jmii.2015.10.006ARC; (3) providing systematic education on stewardship
concepts associated with this policy; (4) enhancing the
participation of infection specialists and pharmacists in
antimicrobial use evaluations based on this policy; and (5)
discussing inappropriate prescriptions with the attending
doctors. Many experts in infection, microbiology, com-
puters and pharmacy from CGMH taught and helped with
the implementation in this local hospital. Unrestricted or
less expensive antibiotics were recommended to replace
the restricted or more expensive ones if both were indi-
cated according to clinically significant cultures. For
example, restricted antimicrobials such as cefuroxime,
ceftriaxone, or ceftazidime were recommended to replace
imipenem, levofloxacin, moxifloxacin, or tazocin if the in-
dications or susceptibilities were similar. Cases of overuse
or inappropriate use of antimicrobials were reported to the
ARC, who discussed it with the prescribers. All staff,
especially the prescribers, were educated to enhance
general adherence to the new policy. Rational use of anti-
microbials guided by clinically significant culture and
infection control was instructed in the morning meetings.Antimicrobial category control policy
The antibiotic prescription control policy classified by un-
restricted and restricted antimicrobials was initiated.bial resistance and defined daily doses after implementation of a
spital, Journal of Microbiology, Immunology and Infection (2015),
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+ MODELUnrestricted antimicrobials were first-line antimicrobials,
including first-generation cephalosporins, penicillin de-
rivatives, aminoglycosides, and other macrolides, such as
cefazolin, clindamycin, and gentamicin, which could be
used clinically by all physicians but were verified regularly
by infectious disease physicians. Restricted antimicrobials
included second-, third-, and fourth-line antimicrobials,
and physicians were required to submit applications to the
members of ARC through the web-based antimicrobial
approval system for their prescription. Restricted antimi-
crobial agents in our institution were: second-, third-, and
fourth-generation cephalosporins (cefuroxime, ceftriax-
one, ceftazidime and flomoxef); broad-spectrum penicillin
derivatives (ampicillin/sulbactam and piperacillin/tazo-
bactam); fluoroquinolones (ciprofloxacin, levofloxacin and
moxifloxacin); glycopeptides (vancomycin and teicoplanin);
carbapenems (imipenem); and others (isepamicin and
tigecycline).
Second-line antimicrobials included second-generation
cephalosporins and aminopenicillins with enzyme in-
hibitors. Third-line antimicrobials were broad-spectrum
antimicrobial agents such as third- and fourth-generation
cephalosporins, antipseudomonal penicillins with enzyme
inhibitors, and fluoroquinolones. Fourth-line agents, such
as imipenem, colistin and tigecycline, were restricted for
the treatment of multiple drug-resistant bacteria. ARC
members conducted clinically significant culture-guided
and bedside evaluations before approving online pre-
scriptions. However, emergency antibiotic prescriptions for
< 2 days were available for instantaneous dispensing to
prevent impeding the treatment of severely sick patients.
Antibiotic usage, dosage, frequency and duration were re-
evaluated by a pharmacist via telephone.Bacterial isolates and antimicrobial susceptibility
All bacteria cultured from any sources, including urine, pus,
sputum, blood, and stools, among patients admitted to
NMGH were collected from 2011 to 2013. All these bacteria
were analyzed for changes in their antibiotic susceptibility
during the study period. Antimicrobial susceptibility was
determined using the disk diffusion method according to
the Clinical and Laboratory Standards Institute standards.28Figure 1. (A) Average antimicrobial cost (US$) and (B) per-
centage of antimicrobial costs in comparison to total costs of
all drugs in each month from 2011 to 2013.DDD
Antibiotic data were determined based on the number of
packages and doses from the retrospective pharmacy
database of the hospital for 2011e2013. These raw data
were entered into Microsoft Excel and converted into DDDs.
The World Health Organization ATC system was used to
identify antimicrobials (ATC/DDD version 2013) and their
adult DDDs as revised in 2012.23 Data were expressed as the
number of DDDs per 100 bed-days of the inpatients. DDDs/
100 bed-days Z annual consumption of antimicrobials
(g)  100 / DDD (g/d)  total hospitalization days.22e26
Data on all intravenous antimicrobials administered to pa-
tients were evaluated in this study.Please cite this article in press as: Wu C-T, et al., Decreased antimicro
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The ARC designed questionnaires were used in the hospital
for evaluating the satisfaction of the attending doctors.
These questionnaires were validated and audited by inde-
pendent administrators, and approved by the hospital su-
perintendent and sent to the attending doctors. All related
staff, including attending doctors and nurses, answered the
questionnaires anonymously in their individual offices. The
questionnaires were collected and summarized by
administrators.
Statistical analysis
Data were recorded and entered into a database. Analyses
were performed using SPSS version 17.0 (SPSS Inc., Chicago,
IL, USA). Student t test, c2 test or Fisher’s exact test was
used when appropriate to compare proportions. All statis-
tical analyses were two-sided, and the significance was set
at p < 0.05.
Results
Patient characteristics
There were 4181 admissions in 2011 during the 1-year
baseline period, and 4230 and 4435 admissions in 2012 and
2013, respectively, during the 2-year intervention period.
Number of monthly admissions increased from 348.4  36.5
in 2011 to 369.6  29.6 (pZ 0.015). Average length of stay
decreased from 7.8  0.5 days in 2011 to 7.2  0.3 days inbial resistance and defined daily doses after implementation of a
spital, Journal of Microbiology, Immunology and Infection (2015),
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+ MODEL2012 (p Z 0.002), then decreased to 6.6  0.3 days
(p < 0.001). Patient characteristics were analyzed. Age,
sex, primary diagnoses, Pitt bacteremia score and Charlson
score were similar between the baseline (2011) and inter-
vention (2012e2013) periods (all p > 0.05; Table 1).
Antimicrobial cost
The average monthly cost of antibiotics decreased by 37.0%
from US$30,146.8 in 2011 to US$18,993.2 in 2012
(p < 0.001; Figure 1A) and by 15.6% from $18,993.2 in 2012
to $16021.3 in 2013 (pZ 0.022; Figure 1A). The percentage
of antimicrobial cost compared with total cost of all drugs
decreased from 19.17% in 2011 to 13.15% in 2012
(p < 0.001; when comparing monthly data throughout the
year; Figure 1B). This percentage decreased from 13.15% in
2012 to 9.59% in 2013 (p < 0.001; Figure 1B).
DDDs
The DDDs of most intravenous antimicrobials, including
cefuroxime, ampicillin/sulbactam, piperacillin/tazo-
bactam, levofloxacin, gentamicin, ceftazidime, isepamicin,
tigecycline, imipenem, flomoxef, clindamycin, and moxi-
floxacin decreased from 2011 to 2013 after implementation
of the new policy (Table 2). However, the DDDs of cefazo-
lin, ceftriaxone, amikacin, sulbactam, tinidazole, cipro-
floxacin and vancomycin increased.
Total intravenous antibiotic DDDs of the inpatients were
21,876.1, 16,534.9, and 14,238.3 in 2011, 2012, and 2013,
respectively (Table 2). The yearly sum of all intravenous
antibiotic DDDs of all intravenous antimicrobials decreased
by 7637.8 (34.9%) from 2011 to 2013. The total bed-days inTable 2 Comparison of defined daily doses (DDDs) of all intrave
Antimicrobials Numbers of DDDs
2011 2012 2013
Cefuroxime 6984.5 3825.0 4001.8
Cefazolin 2071.7 3399.7 2658.0
Ceftriaxone 2064.5 2631.0 2113.5
Augmentin 2916.7 1377.3 948.7
Piperacillin/tazobactam 2007.0 1244.0 897.0
Levofloxacin 811.5 368.0 547.5
Amikacin 236.0 370.0 406.0
Gentamicin 1099.3 428.3 374.3
Ceftazidime 376.8 560.8 374.3
Ampicillin/sulbactam 217.5 180.5 348.0
Isepamicin 657.0 500.0 282.5
Ciprofloxacin 139.6 377.6 272.8
Tigecycline 350.0 163.0 253.0
Imipenem 584.0 319.8 251.0
Vancomycin 231.5 218.3 236.3
Flomoxef 199.8 77.0 127.3
Clindamycin 817.8 320.7 105.5
Moxifloxacin 111.0 174.0 41.0
Sum 21,876.1 16,534.9 14,238
a Change Z Data2013  Data2011.
DDD Z defined daily dose.
Please cite this article in press as: Wu C-T, et al., Decreased antimicro
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http://dx.doi.org/10.1016/j.jmii.2015.10.0062011, 2012 and 2013 were 32,679, 30,584 and 29,429,
respectively. After calculation, the total antibiotic DDDs
per 100 bed-days of inpatients were 66.9, 54.1 and 48.4 in
2011, 2012 and 2013, respectively. A total decrease of 18.6
DDDs (27.7%) per 100 bed-days of the inpatients occurred
from 2011 to 2013.
Microbiological assay
There was no significant difference among distribution of
bacterial sources (urine, pus, sputum, blood, and stools)
from 2011 to 2013 (all p > 0.05). Species identified by
culture are summarized in Table 3. Staphylococcus and
Streptococcus species were predominant among Gram-
positive bacteria (Table 3). Escherichia coli, Klebsiella
pneumoniae and Pseudomonas aeruginosa were leading
species among Gram-negative bacteria. Total number of all
bacteria was reduced by 298 isolates (17.1%) from 2011 to
2013 (Table 3).
Antimicrobial susceptibilities
After comparing susceptibilities to various antimicrobials in
2012 or 2013 to those in 2011, the susceptibilities to anti-
microbials for treating all Gram-positive bacteria increased
from 2011 to 2012 (pZ 0.024, Figure 2A) and also increased
from 2011 to 2013 (p Z 0.013). Susceptibilities to all anti-
microbial agents increased after the ASP, except cefazolin.
The susceptibilities to antimicrobials for treating Staphy-
lococcus aureus, the predominant Gram-positive bacteria,
increased from 2011 to 2012 (p Z 0.002, Table 3) and also
increased from 2011 to 2013 (p Z 0.019). The percentage
of methicillin-resistant Staphylococcus aureus (MRSA) innous antimicrobials used from 2011 to 2013.
DDDs/100 bed-days
Changea 2011 2012 2013 Change
2982.8 21.4 12.5 13.6 7.8
586.3 6.3 11.1 9.0 2.7
49.0 6.3 8.6 7.2 0.9
1968.0 8.9 4.5 3.2 5.7
1110.0 6.1 4.1 3.0 3.1
264.0 2.5 1.2 1.9 0.6
170.0 0.7 1.2 1.4 0.7
725.0 3.4 1.4 1.3 2.1
2.5 1.2 1.8 1.3 0.1
130.5 0.7 0.6 1.2 0.5
374.5 2.0 1.6 1.0 1.1
133.2 0.4 1.2 0.9 0.5
97.0 1.1 0.5 0.9 0.2
333.0 1.8 1.0 0.9 0.9
4.8 0.7 0.7 0.8 0.1
72.5 0.6 0.3 0.4 0.2
712.3 2.5 1.0 0.4 2.1
70.0 0.3 0.6 0.1 0.2
.3 7637.8 66.9 54.1 48.4 18.6
bial resistance and defined daily doses after implementation of a
spital, Journal of Microbiology, Immunology and Infection (2015),
Table 3 Total numbers of bacteria and antibiotic resistance from all Gram-positive cultures from patients admitted in 2011e2013.
Bacterial species Year of
data
Total no. of
bacteria
(%)a
Antibiotic resistance (%)
Clindamycin Gentamicin Penicillin Flucloxacillin Cefazolin Ceftriaxone Ciprofloxacin Levofloxacin Moxifloxacin Vancomycin Tigecycline
Staphylococcus
aureus
Data2011 238 (13.7) 45 26.9 87.8 50.8 30.3 48.7 18.9 13.9 7.6 0 0
Data2012 228 (13.9) 53.1 21.5 79.8 19.7 25 31.6 9.2 7.9 4.8 0 0
Data2013 220 (15.3) 36.8 15.8 71.8 10.5 32.6 30.5 10.0 10.0 5.9 0 0
Enterococcus
species
Data2011 199 (11.4) d 54.8 10.1 70.4 d d 37.7 36.2 0 0 0
Data2012 187 (11.4) d 50.3 10.2 19.8 d d 22.4 15 0 0 0
Data2013 179 (12.4) d 43 2.2 12.3 d d 18.4 16.2 0 0 0
Streptococcus
agalactiae
Data2011 92 (5.3) 26.1 d 22.8 23.9 d 28.3 d 31.5 31.5 0 0
Data2012 78 (4.7) 25.6 d 23.1 21.8 d 11.5 d 14.1 15.4 0 0
Data2013 63 (4.4) 25.4 d 4.8 3.2 d 0 d 11.1 11.1 0 0
Streptococcus
pneumoniae
Data2011 31 (1.8) 32.3 d 67.7 67.7 d 29 d 6.5 6.5 0 0
Data2012 23 (1.4) 30.4 d 69.6 30.4 d 13 d 6.5 6.5 0 0
Data2013 21 (1.5) 23.8 d 4.8 14.3 d 9.5 d 9.5 9.5 0 0
Gram-positive
bacilli
Data2011 21 (1.2) 33.3 23.8 57.1 57.1 19 38.1 33.3 28.5 19 0 0
Data2012 23 (1.4) 26.1 26.1 56.5 43.4 17.4 13 13 28.5 19 0 0
Data2013 20 (1.4) 30 10 45 40 30 25 30 25 25 0 0
Streptococcus
viridians
Data2011 16 (0.9) 37.5 d 37.5 31.3 d 31.3 d 18.8 18.8 0 0
Data2012 18 (1.1) 33.3 d 38.9 22.2 d 22.2 d 18.8 18.8 0 0
Data2013 11 (0.8) 36.3 d 27.2 18.2 d 9.1 d 18.2 9.1 0 0
Streptococcus
pyogens
Data2011 14 (0.8) 28.6 d 0 0 0 0 d 0 0 0 0
Data2012 15 (0.9) 26.7 d 0 0 0 0 d 0 0 0 0
Data2013 13 (0.9) 0 d 0 0 0 0 d 0 0 0 0
Coagulase
-negative
staphylococci
Data2011 12 (0.7) 33.3 50 66.7 50 41.7 41.7 25 25 16.7 0 8.3
Data2012 9 (0.5) 33.3 44.4 66.7 44.4 22.2 22.2 22.2 25 16.7 0 0
Data2013 6 (0.4) 33.3 16.7 50 33.3 16.7 16.7 16.7 16.7 8.3 0 0
a Presented as total number of this species (percentage of all Gram-positive bacteria andGram-negative bacteria, including those in Table 4).
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+ MODELthis species decreased from 50.8% (121/238) to 10.5% (23/
220). No vancomycin-resistant enterococci were found in
the study period.
The susceptibilities to antimicrobials for treating Gram-
negative bacteria increased from 2011 to 2012 (p < 0.001,
Figure 2B), and also from 2011 to 2013 (p < 0.001). The
susceptibilities to antimicrobials for E. coli, the leading
Gram-negative bacteria, increased from 2011 to 2012
(p Z 0.002, Table 4), and increased from 2011 to 2013
(p Z 0.002). Susceptibilities to all antimicrobial agents
increased after the ASP, except ampicillin/sulbactam. The
percentage of imipenem-resistant Acinetobacter bau-
mannii (IRAB) decreased from 74% (37/50) in 2011 to 52.5%
(21/40) in 2013. The percentage of E. coli containing
extended-spectrum b-lactamase decreased from 5.1% (30/
592) to 1.1% (6/545). The percentage of extended-spec-
trum-b-lactamase-producing K. pneumoniae decreased
from 3.9% (7/181) to 2.2% (3/139).
Mortality
The total number of patient deaths decreased from 53 in
2011 to 48 in 2012 and 45 in 2013. The yearly mortality also
decreased from 1.3% in 2011 to 1.1% in 2012 and 1.0% in
2013.
Questionnaire
According to the questionnaire results from 155 related
staff, including 27 attending doctors, 56 nurses, and 72
other staff, > 90% of the doctors believed the new policy
was effective in antibiotic restriction, and reducing anti-
biotic abuse, resistance, and related side effects (Table 5).
More than 85% of the attending doctors were satisfied withFigure 2. Changes in antibiotic resistance of (A) Gram-
positive and (B) Gram-negative bacteria to antimicrobials from
2011 to 2013. Resistance rateZ number of susceptible bacteria
to the antimicrobial / number of total tested bacteria.
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After assessing the economic benefit of this culture-guided
ASP, the average antimicrobial cost and the percentage of
antimicrobial costs in comparison with the total cost of all
drugs were improved from 2011 to 2013. The results indi-
cated that the new antimicrobial restriction policy reduced
the treatment expenditure successfully in this hospital.
Similarly, the extensive implementation of the ASP by
specialized staff was found recently to be effective in
reducing the inappropriate use of antimicrobials and their
costs in Japan, the US and Taiwan.29e36 The decreased
antimicrobial cost around October might be correlated with
less bacterial infections due to the warmer temperatures in
Taiwan.
Antimicrobial resistance decreased in Gram-positive and
Gram-negative bacteria in this hospital. The predominant
species included E. coli, K. pneumoniae, P. aeruginosa and
Staphylococcus aureus. The new antimicrobial restriction
policy reduced the antimicrobial resistance towards almost
all antimicrobials for these bacteria. Only the resistance to
cefazolin increased for Gram-positive bacteria, whereas
the resistance to ampicillin/sulbactam also increased for
Gram-negative bacteria. Cefazolin, if the infection path-
ogen was susceptible to it, was recommended by the ARC as
a substitution for second-, and third- line antimicrobials or
other expensive first-line antimicrobials. Ampicillin/sul-
bactam, if the pathogen was susceptible to it, was recom-
mended in lieu of other expensive restricted
antimicrobials, such as piperacillin/tazobactam, levo-
floxacin, tigecycline, imipenem, flomoxef, and moxi-
floxacin. The increased resistance to cefazolin and
ampicillin/sulbactam could be explained by increased DDDs
after ASP implementation. Therefore, the increased resis-
tance to the two antimicrobials may be attributed to the
implementation of the new restriction policy. In other
studies, the ASPs had significant effects on decreasing the
use of a number of broad-spectrum antimicrobials, but use
of some other antimicrobials might have increased.29e35
After implementing the ASP, for example, prolonged anti-
microbial usage for > 2 weeks was significantly reduced.
Significant reductions in antimicrobial use were observed
for second-generation cephalosporins, carbapenems, and
aminoglycosides,31 and the use of the three antimicrobials
also decreased in our study.
Bias may exist in antimicrobial costs due to the varia-
tions in different antimicrobial prices. DDD is a valuable
tool for assessing the overall quality of prescribed anti-
microbials.22e26 The reductions of 7637.8 DDDs (34.9% of
the total DDDS in 2011) and 18.6 DDDs per 100 bededays of
inpatients (27.7% of the value in 2011) in 2013 demon-
strated successful restriction in antimicrobial usage. Only
the DDDs of cefazolin, ceftriaxone, ceftazidime, amikacin,
ampicillin/sulbactam, ciprofloxacin, and vancomycin
increased after the restriction policy. However, the
increased use of these antimicrobials was attributed to the
recommendation by the ARC to substitute the restricted or
expensive antimicrobials.bial resistance and defined daily doses after implementation of a
spital, Journal of Microbiology, Immunology and Infection (2015),
Table 4 Total numbers of bacteria and antibiotic resistance of all Gram-negative cultures from patients admitted in 2011e2013.
Bacterial species Year of
data
Total no. of
bacteria (%)a
Antibiotic resistance (%)
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Escherichia coli Data2011 592 (34.0) 30.6 9 0 35.6 7.8 29.9 27.5 21.8 14.9 29.7 28.7 27.7 0 0
Data2012 563 (34.2) 25 2 0 36.4 1.8 30 24 17.1 12.8 25 25 25 0 0
Data2013 545 (37.8) 24 0.9 0 30.1 21.7 17.2 11.6 24 24 24 38 0.9 0 0
Klebsiella pneumoniae Data2011 181 (10.4) 40.9 32 33.1 32 11 60.2 51.9 47 37 48.1 48.1 48.1 0 0
Data2012 171 (10.4) 12.9 22.2 12.3 45.6 11.1 50.9 45 22.2 12.9 34.5 38 33.3 0 0
Data2013 139 (9.6) 22.3 12.9 33.1 39.6 39.6 28.8 39.6 28.8 28.8 28.8 39.6 10.1 0 0
Pseudomonas aeruginosa Data2011 184 (10.6) 17.9 3.8 3.8 0 9.8 0 0 0 13 29.9 29.9 29.9 15.2 20.1
Data2012 157 (9.5) 14 3.2 2.5 0 5.1 0 0 0 14 28 27.4 27.4 10.8 14
Data2013 119 (8.3) 21.6 1.7 1.7 0 0 0 3.4 29.4 29.4 24.3 0 4.2 1.7 4.2
Acinetobacter baumannii Data2011 50 (2.9) 96 92 92 82 80 0 0 0 94 94 92 92 74 0
Data2012 50 (3.0) 88 86 84 78 46 0 0 0 94 92 92 92 68 30
Data2013 40 (2.8) 85 80 80 0 0 0 92 92 90 90 62.5 80 52.5 0
Proteus mirabilis Data2011 35 (2.0) 40 20 0 28.6 0 37.1 17.1 11.4 11.4 20 20 20 0 0
Data2012 68 (4.1) 20.6 10.3 0 8.8 0 11.8 17.1 11.4 7.4 11.8 8.8 8.8 0 0
Data2013 25 (1.7) 20 0 0 8 0 0 0 8 8 8 4 0 0 0
Salmonella species Data2011 58 (3.3) 0 0 0 39.7 0 0 0 0 0 0 0 0 0 0
Data2012 28 (1.7) 0 0 0 10.3 0 0 0 0 0 0 0 0 0 0
Data2013 21 (1.5) 0 0 0 0 0 4.8 0 4.8 4.8 0 14.3 0 0 0
Escherichia fergusonii Data2011 16 (0.9) 25 12.5 0 25 12.5 18.8 18.8 12.5 6.3 18.8 12.5 12.5 0 0
Data2012 26 (1.6) 26.9 11.5 0 26.9 11.5 15.4 15.4 11.5 11.5 15.4 11.5 11.5 0 0
Data2013 19 (1.3) 26.3 10.5 0 15.8 10.5 10.5 5.3 10.5 10.5 10.5 15.8 0 0 0
a Presented as total number of this species (percentage of all Gram-positive and Gram-negative bacteria, including those in Table 3).
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Table 5 Results of the questionnaire about the novel antibiotic restriction policy with the antimicrobial stewardship program.
Questions Excellent or
very satisfied
n (%)
Yes or
satisfied
n (%)
No or
dissatisfied
n (%)
Poor or very
dissatisfied
n (%)
Is the policy effective in antibiotic abuse? 76 (49.0) 79 (51.0) 0 (0) 0 (0)
Is the policy effective in reducing
antibiotic resistance?
56 (36.2) 85 (54.8) 14 (9.0) 0 (0)
Is the policy effective in decreasing
antibiotic-related side effects?
81 (52.3) 72 (46.5) 2 (1.3) 0 (0)
Is the policy effective in antibiotic
restriction?
63 (40.6) 86 (55.5) 6 (3.9) 0 (0)
Are you satisfied with the policy in
antibiotic restriction?
29 (18.7) 108 (69.7) 18 (11.6) 0 (0)
Are you satisfied with web-based
antibiotic audit system?
28 (18.1) 104 (67.1) 23 (14.8) 0 (0)
Are you satisfied with antibiotic
audit system?
29 (18.7) 115 (74.2) 11 (7.1%) 0 (0)
Are you satisfied with the novel policy? 29 (18.7) 120 (77.4) 6 (3.9%) 0 (0)
Culture-guided antimicrobial stewardship program 9
+ MODELWe excluded the bias of disease severity because there
was no significant difference in Pitt bacteremia score and
Charlson score from 2011 to 2013 (Table 1). In order to
avoid confounding by antibiotic policy other than the
culture-based regimen, we used the data in 2011 as a
control since traditional antibiotic policy other than the
culture-based regimen has been performed in 2011. We
excluded the bias of difference in admission population
because there was no significant difference among age,
sex, and primary ICD-9 codes and Charlson score of
admitted patients during the control and study periods
(Table 1). Since there was no significant population differ-
ence among admitted patients from 2011 to 2013, the bias
caused by antimicrobial resistance in the community before
admission was equally distributed in the control group in
2011 and the study group in 2012e2013; thus, the bias could
be excluded after comparing the data of the study group
and control group. There was no different infection control
policy leading to any confounding factor during the study
period.
This study highlighted the decreased antimicrobial
resistance associated with the reduced DDDs. Similarly, in a
previous multivariate analysis, the piperacillin/tazo-
bactam, quinolones, and/or total consumption at the
advanced treatment hospitals showed a significant corre-
lation with the incidence of P. aeruginosa resistant to imi-
penem, meropenem, ciprofloxacin, and amikacin.29 The
incidence of A. baumannii resistant to imipenem correlated
with the use of broad-spectrum antimicrobials for at least
5 days.4e6 The prevalence of multi-drug-resistant A. bau-
mannii isolated during the carbapenem non-restricted
period was at least twofold higher than that during the
carbapenem-restricted period.37
Use of cephalosporins and fluoroquinolones is an inde-
pendent risk factor for MRSA infections.38,39 By this princi-
ple, decreased total consumption of cephalosporins (d4.1
DDDs/100 bed-days from 2011 to 2013) and fluo-
roquinolones (0.3 DDDs/100 bed-days from 2011 to 2013)
could explain the decreased percentage of MRSA in this
species (50.8% in 2011 to 10.5% in 2013). Prior use of broad-Please cite this article in press as: Wu C-T, et al., Decreased antimicro
clinical culture-guided antimicrobial stewardship program in a local ho
http://dx.doi.org/10.1016/j.jmii.2015.10.006spectrum antibiotics is an independent risk factor for IRAB
infections.4,5 Thus, the decreased percentage of IRAB (74%
in 2011 to 52.5% in 2013) could be explained by the
decreased total consumption of broad-spectrum antibiotics
in this study (Table 2).
In conclusion, we report successful implementation of a
culture-guided ASP, an antimicrobial restriction policy,
leading to medical expense savings, and decreases in the
inappropriate use of antimicrobials, average length of stay,
mortality, and development of antimicrobial resistance.
With the advantage of our experience, the implementation
of practical ASP is highly recommended for local hospitals.
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